GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » Cyclically Adjusted Price-to-FCF

Affymax (Affymax) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Affymax Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Affymax Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Affymax's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax Cyclically Adjusted Price-to-FCF Chart

Affymax Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Affymax Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Affymax's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Affymax's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymax's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Affymax's Cyclically Adjusted Price-to-FCF falls into.



Affymax Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Affymax's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2014 is calculated as:

For example, Affymax's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2014 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=-0.039/100.5595*100.5595
=-0.039

Current CPI (Jun. 2014) = 100.5595.

Affymax Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200409 0.000 80.121 0.000
200412 0.000 80.290 0.000
200503 0.000 81.555 0.000
200506 0.000 82.062 0.000
200509 0.000 83.876 0.000
200512 0.000 83.032 0.000
200603 24.180 84.298 28.845
200606 -6.074 85.606 -7.135
200609 56.772 85.606 66.689
200612 -0.627 85.142 -0.741
200703 -0.249 86.640 -0.289
200706 -0.622 87.906 -0.712
200709 -1.022 87.964 -1.168
200712 -1.381 88.616 -1.567
200803 -0.495 90.090 -0.553
200806 -0.836 92.320 -0.911
200809 -2.083 92.307 -2.269
200812 -0.945 88.697 -1.071
200903 -0.904 89.744 -1.013
200906 -1.141 91.003 -1.261
200909 -1.028 91.120 -1.134
200912 -1.211 91.111 -1.337
201003 -0.622 91.821 -0.681
201006 0.183 91.962 0.200
201009 -0.644 92.162 -0.703
201012 -0.939 92.474 -1.021
201103 -0.728 94.283 -0.776
201106 -0.820 95.235 -0.866
201109 -0.224 95.727 -0.235
201112 -0.477 95.213 -0.504
201203 -0.481 96.783 -0.500
201206 0.691 96.819 0.718
201209 -0.604 97.633 -0.622
201212 -0.719 96.871 -0.746
201303 -0.657 98.209 -0.673
201306 -0.975 98.518 -0.995
201309 -0.131 98.790 -0.133
201312 -0.034 98.326 -0.035
201403 -0.020 99.695 -0.020
201406 -0.039 100.560 -0.039

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affymax  (OTCPK:AFFY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Affymax Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Affymax's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymax (Affymax) Business Description

Industry
Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Executives
John Peter Walker director 126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson officer: Chief Financial Officer 8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp officer: Chief Commercial Officer 4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege officer: Chief Medical Officer 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte director
Karin L Walker officer: VP, Finance & CAO C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton director
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland officer: EVP, Corp. Development and CFO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris director, officer: CEO C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor 09-30-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor 05-19-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor 05-13-2010